(Q43717920)

26 November 2017

1 reference

title

Cross-clade T cell recognition of HIV.1. (English)

1 reference

26 November 2017

Gotch F

1

1 reference

26 November 2017

publication date

1 August 1998

1 reference

Current Opinion in Immunology

26 November 2017

published in

1 reference

26 November 2017

volume

10

1 reference

26 November 2017

issue

4

1 reference

26 November 2017

page(s)

388-392

1 reference

Human immunodeficiency virus infection and other sexually transmitted diseases in developing countries: public health importance and priorities for resource allocation

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980109-X

7 January 2021

Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980109-X

7 January 2021

hu-PBL-SCID mice can be protected from HIV-1 infection by passive transfer of monoclonal antibody to the principal neutralizing determinant of envelope gp120

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980109-X

7 January 2021

Dilemma of neutralization resistance of HIV-1 field isolates and vaccine development.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980109-X

7 January 2021

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Ev

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980109-X

7 January 2021

Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980109-X

7 January 2021

CD4+ T-cell recognition of diverse clade B HIV-1 isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980109-X

7 January 2021

Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980109-X

7 January 2021

Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980109-X

7 January 2021

Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980109-X

7 January 2021

HIV-2-specific cytotoxic T-lymphocyte activity is inversely related to proviral load

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980109-X

7 January 2021

Persistent high frequency of human immunodeficiency virus-specific cytotoxic T cells in peripheral blood of infected donors

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980109-X

7 January 2021

HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980109-X

7 January 2021

HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980109-X

7 January 2021

Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980109-X

7 January 2021

Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980109-X

7 January 2021

Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980109-X

7 January 2021

Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp 160 of HIV-1 and boosted with a recombinant gp160.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980109-X

7 January 2021

DNA inoculation induces cross clade anti-HIV-1 responses

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980109-X

7 January 2021

Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980109-X

7 January 2021

Amino-terminal alteration of the HLA-A*0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980109-X

7 January 2021

Cross-clade recognition of p55 by cytotoxic T lymphocytes in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980109-X

7 January 2021

Reduced rate of disease development after HIV-2 infection as compared to HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980109-X

7 January 2021

Vaccine protection by a triple deletion mutant of simian immunodeficiency virus.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980109-X

7 January 2021

10.1016/S0952-7915(98)80109-X

Identifiers

DOI

1 reference

26 November 2017

1 reference